Tag: HSO

Is Healthscope about to give up its battle to remain independent? It yesterday offered exclusive due diligence to Brookfield Capital Partners after the Canadian-led investor group returned to the table with a takeover offer worth up to $4.5 billion.

Act 2 of the same corporate play has seen Healthscope on the end of a second unsolicited bid from the BGH-AustralianSuper Consortium.

Private hospitals group Healthscope wants a co-investor after it confirmed that wants to sell most of its $1 billion hospital assets and lease them back.

Private hospital operator Healthscope has responded to the pressure from two unwanted takeover offers from private equity and decided it will sell its Asian pathology business for $279 million to entities controlled by funds managed by TPG Capital Asia.

Healthscope has pulled up the drawbridge and told the raiders to go away via two statements issued yesterday.

There’s a takeover battle for private hospital operator Healthscope which yesterday received its second takeover in a couple of weeks, this time from a Canadian investment group.

You can’t help being cynical about the second private equity grab for hospitals group, Healthscope in 8 years. The $4.1 billion the opportunistic bid won accolades this morning from the usual cheer squads in the business media on Friday morning. The Financial Review’s Chanticleer described it as “exquisitely timed”. Others praised it as a property play, selling off and leasing back the private hospitals and other assets, but failed to note that this and any extra debt, would add more costs to the health budgets of millions of people and the country.

A first bid try on from a group of private investors trying to snatch Healthscope on the cheap?

The nation’s second largest private hospitals operator Healthscope has joined its sector peers in the shape of Sonic and Primary Health Care in a less than spectacular performance in 2016-17.

A year ago, Healthscope (HSO) surprised investors by producing a disappointing full year earnings performance that missed its own guidance. That sent the shares down 5% to just under $2.50.